" Alterity is continuing to explore clinical development options for PBT2 outside the area of neurodegenerative diseases". So what are these?
What comes to my mind are:
1. Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.
2. Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance.
IMO in both of these, we need clinical studies. Most likely new patents or patent applications.
Ann: Appendix 4E & Annual Report 2019, page-3
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $184.6K | 61.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 75735096 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 33814069 | 6 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |